Moreover, there was a trend towards patients with H3-WT tumours and ACVR1 mutations being older than patients with H3-WT and EGFR mutant tumours (median = 10 years [range 5–15] and median = 3.5 years [range 1–16], respectively), although no significant difference was observed (p = 0.265; Fig. 3D). This evidence concerns the gene EGFR and neoplasm.